Tagged with M

Opinion The AAM’s Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry faces from the Lower Health Care Costs Act.   A key provision of our generic pharmaceutical architecture is in jeopardy. The “180-day exclusivity” is the…

CEE Here we highlight five of the most important women working in healthcare and the life sciences in Central & Eastern Europe (CEE) today. From regulators to pharma affiliate heads with international remits, these are some of the key movers and shakers in the region’s pharma industry.   Irena Storová, director,…

Romania Healthcare spending in Romania in comparison to the EU average. Made with Visme Infographic Maker   Romania spends the least on healthcare as a proportion of its GDP in the entire EU. Made with Visme Infographic Maker     Out of pocket healthcare spending in Romania as a proportion of…

Czech Republic Czech Republic’s overall pharma market value increased 5 per cent in 2019, while its units produced decreased by 1 per cent.   Made with Visme Presentation Maker   The number of clinical trials conducted in the Czech Republic increased in 2017 and fell to a three-year low in 2018. Made…

Czech Republic These are the 20 pharma companies in the Czech Republic, ranked by sales for the period between October 2018 and October 2019. Novartis came out on top with annual sales of USD 251.4 million, followed by Sanofi with USD 170.9 million and Roche with USD 149.8 million. Made with Visme…

Korea Multinational pharma company managers working abroad must adapt to new cultures and develop a deep understanding of local markets. Korea is no different; here three foreign country managers give their first impressions and insights into the Korean pharma market.   Nic Horridge, Roche   As a newcomer in the land…

China Mike Chen, president and CEO of ACROBiosystems, shares his global success as a manufacturer of recombinant proteins supporting biologics R&D and how he hopes to expand his business to eventually set up a multifaceted platform for MNCs and biotechs.   By having a manufacturing facility in the USA or Europe,…

Hungary Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s first company-developed biosimilar in Japan.   Our advancement in biotechnology has been a key development for Gedeon Richter this year…

UAE Cara Nazari of AmCham Dubai discusses her role in helping shape the chamber into a more business-minded institution, why Dubai is an attractive destination for investment, improving healthcare stakeholder relations, and fostering ‘Open Innovation’.   Healthcare is a top priority for the UAE. Ensuring quality care for its population is…

Hungary Dr Péter Holchacker, director of the Hungarian Association of Innovative Pharmaceutical Manufacturers (AIPM), shares his insights on the key activities of the organisation, the collaborations it fosters with authorities and multinational pharmaceutical companies, the attractiveness of the Hungarian market, and the AIPM’s role in improving the country’s regulatory and reimbursement…

Hungary Attila Lukács, general manager Hungary, Romania, Bulgaria for CSL Behring outlines emergent trends in the Hungarian plasma medication market, how the affiliate has succeeded in becoming a partner to patient associations in Hungary, and his strategic priorities for the future.   What I am most proud of is how we…

UAE Samir Khalil, executive director for the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa (MEA), reveals why the US industry is investing in MEA, the challenges presented by the lack of intellectual property enforcement in the region, and the shifting of focus from manufacturing to broader research…